Rheumatic-heart disease management sales will grow through 2036, led by valve products at 61.4% of the product category in 2026. The market was valued at USD 1.43 billion in 2025 and is expected to be worth USD 2.2 billion by 2036, creating an incremental opportunity of USD 0.71 billion.